Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
暂无分享,去创建一个
G. Comi | H. Butzkueven | G. Edan | R. Fox | A. van der Walt | A. Salter | R. Middleton | R. Nicholas | L. Geys | J. Hillert | I. van der Mei | M. F. Mendes | T. Spelman | S. Ozakbas | T. Kalincik | R. Alroughani | L. Peeters | N. Nag | A. Glaser | A. Stahmann | M. Magyari | J. Rojas | R. Alonso | S. Simpson-Yap | H. Schmidt | A. Bergmann | S. Braune | Y. Moreau | G. Arrambide | Clare Walton | N. Rijke | D. Brum | A. Chertcoff | L. Forsberg | Tina Parciak | N. Lazovski | E. De Brouwer | Guilherme Sciascia do Olival | A. Dias | R. McBurney | J. Bauer | A. Pirmani | Clément Gautrais | Amin Ardeshirdavanai | R. Ivanov | Anna Zabalza | A. Fidao | Alexander Fidao | I. A. van der Mei | Nikola Lazovski | T. Parciak | Ana Zabalza
[1] G. Cutter,et al. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis , 2021, JAMA neurology.
[2] T. Friede,et al. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[3] Yves Moreau,et al. COVID-19 in people with multiple sclerosis: A global data sharing initiative , 2020, Multiple sclerosis.
[4] C. Louapre,et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. , 2020, JAMA neurology.
[5] M. Sormani,et al. Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis , 2020, SSRN Electronic Journal.
[6] K. Schmierer,et al. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic , 2020, Multiple Sclerosis and Related Disorders.
[7] T. Olsson,et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. , 2020, JAMA neurology.
[8] D. Arnold,et al. Effect of dimethyl fumarate on lymphocytes in RRMS , 2019, Neurology.
[9] T. Holmøy,et al. B cell depletion in the treatment of multiple sclerosis , 2019, Expert opinion on biological therapy.
[10] Yinshan Zhao,et al. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[11] S. Hauser,et al. Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis , 2017, Neurotherapeutics.
[12] Ludwig Kappos,et al. Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study , 2017, Multiple sclerosis.
[13] K. Dear,et al. The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: The Ausimmune study , 2013, Multiple sclerosis.
[14] C. Klein,et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties , 2013, mAbs.
[15] T. Dwyer,et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis , 2009, Journal of Neurology.
[16] R. Marrie,et al. Smoking Status over Two Years in Patients with Multiple Sclerosis , 2008, Neuroepidemiology.
[17] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.